Gristick HB, Hartweger H, Loewe M, van Schooten J, Ramos V, Oliveira TY, Nishimura Y, Koranda NS, Wall A, Yao K-H et al..  2023.  CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals.. Sci Immunol. 8(80):eade6364.

Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A, Agudelo M, Finkin S et al..  2021.  Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.. Nat Commun. 12(1):4196.

Keeffe JR, Van Rompay KKA, Olsen PC, Wang Q, Gazumyan A, Azzopardi SA, Schaefer-Babajew D, Lee YE, Stuart JB, Singapuri A et al..  2018.  A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.. Cell Rep. 25(6):1385-1394.e7.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)

Verma N, Zhu Z, Huangfu D.  2017.  CRISPR/Cas-Mediated Knockin in Human Pluripotent Stem Cells.. Methods Mol Biol. 1513:119-140.

Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA.  2016.  Opportunities and challenges for TCR mimic antibodies in cancer therapy.. Expert Opin Biol Ther. 16(8):979-87.

Gautam S, Kim T, Lester E, Deep D, Spiegel DA.  2016.  Wall teichoic acids prevent antibody binding to epitopes within the cell wall of Staphylococcus aureus.. ACS Chem Biol. 11(1):25-30.

Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB.  2009.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.. J Clin Invest. 119(7):2042-51.